327,058 Shares in Maplight Therapeutics, Inc. $MPLT Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 327,058 shares of the company’s stock, valued at approximately $5,745,000. Maplight Therapeutics accounts for approximately 0.4% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 18th largest holding.

Separately, Strs Ohio acquired a new stake in shares of Maplight Therapeutics in the 4th quarter worth about $53,000.

Insider Transactions at Maplight Therapeutics

In other news, insider Jonathan Gillis sold 51,900 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $29.74, for a total transaction of $1,543,506.00. Following the completion of the transaction, the insider owned 199,154 shares in the company, valued at approximately $5,922,839.96. This trade represents a 20.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Anatol Kreitzer sold 45,422 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $29.66, for a total transaction of $1,347,216.52. Following the transaction, the insider owned 211,190 shares of the company’s stock, valued at approximately $6,263,895.40. This trade represents a 17.70% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 495,980 shares of company stock worth $14,092,819 over the last ninety days. Insiders own 3.80% of the company’s stock.

Maplight Therapeutics Price Performance

Shares of MPLT opened at $28.75 on Monday. The firm has a 50-day moving average price of $25.14 and a 200 day moving average price of $20.04. The firm has a market capitalization of $1.23 billion and a PE ratio of -0.70. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). On average, equities analysts expect that Maplight Therapeutics, Inc. will post -4.45 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Maplight Therapeutics in a report on Thursday, March 19th. They issued a “buy” rating and a $35.00 price objective on the stock. Lifesci Capital raised shares of Maplight Therapeutics to a “strong-buy” rating in a report on Thursday, May 14th. Needham & Company LLC assumed coverage on shares of Maplight Therapeutics in a research report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price for the company. Craig Hallum assumed coverage on shares of Maplight Therapeutics in a research report on Thursday. They issued a “buy” rating and a $43.00 target price for the company. Finally, Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Maplight Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Maplight Therapeutics Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.